Description: RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.
Home Page: www.redhillbio.com
RDHL Technical Analysis
21 Ha’arba’a Street
Tel Aviv,
6473921
Israel
Phone:
972 3 541 3131
Officers
Name | Title |
---|---|
Mr. Dror Ben-Asher | Co-Founder, Chairman & CEO |
Mr. Micha Ben-Chorin | Chief Financial Officer |
Mr. Gilead Raday MPhil, MSc | Chief Operating Officer |
Mr. Adi Frish | Chief Corp. & Bus. Devel. Officer |
Mr. Rick D. Scruggs | Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director |
Dr. Mark L. Levitt M.D., Ph.D. | Chief Scientific Officer |
Ms. Alexandra Okmian | Sr. Bus. Devel. & Investor Relations Mang. |
Kristin Comer | VP, Gen. Counsel & Chief Compliance Officer |
Ms. Valerie Graceffa | VP of Sales |
Mr. Rob Jackson | Sr. VP of Sales & Marketing |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 1428.5714 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 4.6005 |
Price-to-Sales TTM: | 0.2159 |
IPO Date: | 2013-01-07 |
Fiscal Year End: | December |
Full Time Employees: | 201 |